Sandip Pravin Patel
Overview
Explore the profile of Sandip Pravin Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
2938
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luke J, Sweis R, Hecht J, Schneider R, Stein M, Golan T, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39846804
Background: We evaluated the non-cyclic dinucleotide stimulator of interferon genes agonist MK-2118 ± pembrolizumab in patients with advanced solid tumors or lymphomas. Methods: This first-in-human study (NCT03249792) enrolled patients with...
2.
Shiller M, Johnson M, Auber R, Patel S
Front Oncol
. 2024 Dec;
14:1459737.
PMID: 39703851
Standard first-line therapy for patients with metastatic non-small cell lung cancer (mNSCLC) without identified actionable mutations consists of regimens comprising immune checkpoint inhibitors (ICIs), alone or in combination with platinum-based...
3.
Chae Y, Othus M, Patel S, Gerber D, Tanvetyanon T, Kim H, et al.
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241293401.
PMID: 39583952
Background: Anti-programmed death-1 (PD-1)/cytotoxic T lymphocyte antigen-4 antibodies are efficacious in various malignancies. Objectives: This study presents the first results of ipilimumab-nivolumab in invasive mucinous or non-mucinous lepidic adenocarcinoma (invasive...
4.
Chae Y, Corthell L, Patel S, Edwards R, Scalici J, Kim H, et al.
Clin Cancer Res
. 2024 Nov;
31(2):308-315.
PMID: 39561273
Purpose: Dual PD-1/CTLA-4 inhibition shows promise in various malignancies. The SWOG S1609 Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) trial presents initial results of ipilimumab/nivolumab in vulvar cancers....
5.
Ferreira Bruzzi Porto H, C K Lopes G, B V Bekierman H, Altino De Almeida S, Da Matta Andreiuolo F, Lucena E, et al.
Case Rep Oncol
. 2024 Oct;
17(1):950-959.
PMID: 39474562
Introduction: High-grade treatment-emergent neuroendocrine prostate cancer (T-NEPC) is a rare subtype of prostate cancer with limited therapeutic options and poor prognosis. Understanding biomarkers that influence the efficacy of immune checkpoint...
6.
Chae Y, Othus M, Patel S, Wilkinson K, Whitman-Purves E, Lea J, et al.
Clin Cancer Res
. 2024 Oct;
30(24):5593-5600.
PMID: 39417692
Purpose: The role of dual checkpoint inhibition (ipilimumab at 1 mg/kg intravenously every 6 weeks and nivolumab at 240 mg intravenously every 2 weeks) in advanced rare/ultrarare nonepithelial ovarian cancers...
7.
Mathews I, Saminathan P, Henglin M, Liu M, Nadig N, Fang C, et al.
medRxiv
. 2024 Aug;
PMID: 39148854
Immune related adverse events (irAEs) after immune checkpoint blockade (ICB) therapy occur in a significant proportion of cancer patients. To date, the circulating mediators of ICB-irAEs remain poorly understood. Using...
8.
Poore G, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, et al.
Nature
. 2024 Jun;
631(8021):694.
PMID: 38926587
No abstract available.
9.
Sepich-Poore G, McDonald D, Kopylova E, Guccione C, Zhu Q, Austin G, et al.
Oncogene
. 2024 Apr;
43(20):1579.
PMID: 38580705
No abstract available.
10.
Patel S, Wang R, Zhou S, Sheinson D, Johnson A, Lee J
JCO Clin Cancer Inform
. 2024 Mar;
8:e2300165.
PMID: 38502111
Purpose: Real-world lung cancer data in administrative claims databases often lack staging information and specific diagnostic codes for lung cancer histology subtypes. This study updates and validates Turner's 2017 treatment-based...